Abstract: Objective To summarize the clinicopathologic features of patients with gastric cancer at stage I-III and their treatment and survival rules after operation. Methods Clinical data about 827 patients with gastric cancer at stage I-III admitted to our hospital from January 2003 to December 2008 for radical surgery were retrospectively analyzed. Relation of their clinicopathologic features and treatment with their survival time and prognosis was also analyzed. Results Of the 827 patients who were followed up for 58.2 months, 507 developed recurrence or metastasis of gastric cancer and 457 died. The median disease-free survival time was 26.6 months and the median survival time was 39.7 months. The 5-year disease-free survival rate was 37.9% and the overall survival rate was 43.8%. Univariate analysis showed that the disease–free survival time and the median survival time were significantly shorter in patients with positive surgical margin, signet ring cell cancer, Lauren diffuse and mixed type, poor and moderate differentiation, vessel cancer embolus, neural cell infiltration, tumor diameter≥5 cm, late TNM stage and non-adjuvant chemotherapy after total gastrectomy than in those with negative surgical margin, no signet ring cell cancer, Lauren intestinal peristalsis, moderate and high differentiation, no vessel cancer embolus, no neural cell infiltration, tumor diameter< 5 cm, early TNM stage, and adjuvant chemotherapy after gastrectomy (P< 0.05). Multivariate COX regression analysis displayed that total gastrectomy, positive surgical margin, adjuvant chemotherapy, TNM stage were the independent factors for the prognosis of disease-free and overall survival time of gastric cancer patients. Conclusion Adjuvant chemotherapy can increase the disease-free and overall survival time of gastric cancer patients after operation.